GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SynAct Pharma SYNACT.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

15.28

0.00%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SynAct Pharma

Its shares trade on Nasdaq Stockholm under the ticker SYNACT.ST. It has been listed since 11 July 2016.

SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
11 Jul 2016
Employees
3

Leadership

Pay as last reported

  • Mr. Anders KronborgChairman of the Board, since 2024
  • Mr. Jeppe OevlesenChief Executive Officer, Director, since 2015SEK 3.7m
  • Mr. Bjoern WestbergChief Financial Officer
  • Dr. Thomas BoesenChief Operating Officer
  • Dr. Thomas JonassenChief Scientific Officer, since 2016SEK 1.9m
  • Mr. Mads BjerregaardChief Business Officer
  • Dr. Sten ScheibyeDirector
  • Mr. Sten SorensenDirector
  • Mr. Jeppe AndersenIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SynAct Pharma AB develops innovative drugs for inflammatory diseases in Lund, Sweden.
  • AP1189 targets arthritis and psoriasis arthritis with potential market impact.
  • The company has a focused team of three employees dedicated to biotechnology research.

Weaknesses

  • SynAct Pharma AB has only three employees, limiting operational capacity.
  • The company's IPO in 2016 shows limited market presence and growth potential.
  • AP1189 is the sole drug candidate, creating dependency on a single product.

Opportunities

  • Sweden's strong biotechnology sector supports SynAct Pharma AB's research and development efforts.
  • The global market for inflammatory disease treatments offers significant growth potential.
  • Collaborations with larger pharmaceutical firms could accelerate AP1189's development.

Threats

  • Competition from established pharmaceutical companies in the Health Care sector poses a risk.
  • Regulatory hurdles in drug approval processes may delay AP1189's market entry.
  • Economic downturns could reduce funding for biotechnology startups like SynAct Pharma AB.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.